IM8 brand growth - IM8 drove Q2 results, marking sixth consecutive record quarter, per CEO Danny Yeung
Record July - July was IM8's strongest month ever, reaching $20.9 mln in revenue, per company statement
Positive cash flow - Company achieved positive adjusted free cash flow for first time, expects it to remain positive, per CEO Danny Yeung
Analyst coverage and target
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
Wall Street's median 12-month price target for Prenetics Global Ltd is $30.00, about 54.9% above its August 17 closing price of $19.37
Raised outlook for 2026 and 2027
Prenetics raises 2026 total revenue guidance to $220-230 mln
Company initiates 2027 IM8 revenue guidance of $400 mln or more
Prenetics expects consolidated adjusted free cash flow to remain positive
Q2 revenue rises on IM8 brand growth
Consumer health company's Q2 revenue rose about 288% yr/yr, driven by IM8 brand growth
PRE•
